Chemomab Q1 net loss $5.1M; cash $57.5M; advancing CM-101 in PSC and SSc

Chemomab Therapeutics Ltd.

2023-Q1 EPS reported $0.02

Net loss of $5.1M ($0.02 per share) vs $1.7M in Q1 2021; R&D expenses $2.7M, G&A $2.6M (incl $0.9M stock comp).
Cash and equivalents $57.5M at March 31, 2022, down from $61.2M at Dec 31, 2021.
Completed enrollment in Phase 2 liver fibrosis study; interim PSC readout expected late 2022; SSc Phase 2 launch planned by year-end.
Appointed Jack Lawler as VP of Global Clinical Development Operations.
Presented CCL24 data at SSc congress; findings support CM-101's role in fibrosis and endothelial damage.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.